CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a Phase 3-ready disease-modifying digital therapeutics company developing a new category of therapeutic treatments for neurodegenerative diseases starting with Alzheimer’s Disease, today announced that Brent Vaughan, CEO, will participate in a fireside chat at the BTIG Biotechnology Conference 2021 on Monday, August 9, 2021 from 11:00-11:25 am ET.
BTIG hosted events are intended for prospective and existing BTIG clients only. To listen to the live event, please contact your BTIG representative.
About Cognito Therapeutics
Cognito Therapeutics is a clinical-stage company developing a pipeline of disease-modifying digital therapeutics targeting neurodegenerative disorders. Its non-invasive neuromodulation platform was based on technology developed by MIT Professors and scientific founders Li-Huei Tsai and Ed Boyden. The Company’s lead digital therapeutic reported positive Phase 2 results in Alzheimer’s Disease, and was awarded FDA Breakthrough Device Designation. Cognito is based in Cambridge, MA. For more information, visit www.cognitotx.com. Follow us on Twitter at @cognitotx.
